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A COMPARATIVE STUDY OF THE AVAILABILITY OF SULPHAFURAZOLE FROM COM·
MERCIAL BRANDS OF SULPHAFURAZOLE TABLETS
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The following differential equations are propo ed to
de cribe Ihe model:
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PHARl\.1ACOKINETIC MODEL
The following pharmacokinetic model is presented to
describe the kinetics of sulphafurazole absorption, meta-
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TABLE I. ANALYTICAL DATA, AND RATE A D OTHER co STANTS











- = klA - (k,B + k,B)
dt








le has been shown by everal authors that the physical
propertie of a drug, uch a particle size, solubility, dis-
olution rate, etc., may have an effect on the biological
availability of the drug.]-· In the course of a tudy aimed
at the determination of the effect of variables in the
formulation of ulphafurazole tablets on the biological
availability of this drug, pharmacokinetic parameters for
sulphafurazole were determined as part of the preliminary
investigation, using 4 brand of local commercially
available sulphafurazole tablets.
The tablets were administered after an alkali load in
order to eliminate diurnal fluctuation in urinary pH.
ovember 1969 S.A. TYDSKRIF VIR GE EESKU DE








































Fig. 1. rinary excretion of sulphafurazole (subject A, product B) under controlled
alkaline urine conditions after oral administration of 1,000 mg. of drug. 0 = experi-
mental values; ..... = free drug (hourly): ---- = free drug (cumulative):
-.-.- = acetylated drug (hourly): = acetylated drug (cumulative).
where t = time in hours after ingestion of the dose;
lag the time interval between ingestion of the dose and
commencement of absorption;
A concentration of sulphafurazole in gastro-intestinal
tract;
B concentration of sulphafurazole in the body:
M concentration of metabolites of sulphafurazole in
body;
concentration of free sulphafurazole in urine;
Urn concentration of metabolites in urine:
k, rate constant for the absorption of sulphafurazole
from the tract into the body:
k, rate constant for the excretion of free sulpha-
furazole from the body into the urine:
k, rate constant for the formation of metabolites of
sulphafurazole:
k, rate constant for the excretion of metabolite from
the body into the urine:
K rate constant for the elimination of sulphafurazole
by all processes, i.e. K = k, + k,.
Two tablets (1,000 mg. sulphafurazole) were admini-
stered, on fasting stomach, to 3 male subject in apparent
good health. 0 ingestion (If food was allowed until at
least 2 hours after the tablets had been taken. Alkaline
urine condition were maintained by ingesting approxi-
mately 4 G of odium bicarbonate J'5 hour before the
tablet were taken, followed by the ame dose every 3
hours. rine sample were collected hourly for at lea t the
first 5' hours after ingestion of the tablets. Thereafter
sample were collected at increasing intervals up to the
times stated in Table I. Treating a sample collected be-
fore dosage of the drug as a blank. the urine ample
were assayed for free and total ulphafurazole by the
Bratton and Marsball method.'
RESULT D 01 USStO
Analytical data a well a the computed rate and other
con tants involved in the absorption, metaboli m and ex-
cretion of sUlphafurazole are li ted in Table I. The
theoretical curves, defined by the above equation, for
ubject A (product B) are hown in Fig. I. The experi-
mental value are in close agreement with tho e com-
puted from the differential equation, and the propo ed
model may be accepted as uitable to de cribe the kinetic
of the absorption. metabolism and excretion of ulpha-
furazole.
The tablets used in the study are of unknown compo i-
tion, but differences in the formation, manufacturing pro-
cedures, and raw materials used must be as umed a most
likely becau e the tablet are being manufactured by
4 different local pharmaceutical companie . Thi assump-
tion is confirmed by difference found in the content of
. ulphafurazole. appearance, hardness, average weight, and
disintegration time of the different products. The pharma-
cokinetic parameters, on the other hand, show hardly
any differences. In all cases absorption of the drug starts
within a reasonably short period of time, and the peak
urinary concentration is reached in 2 - 4 hours. The eli-
mination half-life of free drug. on which the do age in-
terval is ba ed. is of the same order for all 4 products.
ranging from approximately 4 to 5 hours. In the light of
these similarities. the products should be regarded as
equally effective.
SU 1MARY
Urinary excretion data were used in a comparative study of
the biological availability of sulphafurazole from 4 commercial
brands of sulphafurazole tablets. The tablets were administered
after an alkali load. rine sample were assayed for free
and total ulphonamide content and from the experimental
values the rate and other constants involved in the absorption,
metaboli m and excretion of ulphafurazole were computed
by means of differential equations proposed to de cribe a
pharmacokinetic model. Experimental values were in close
agreement with computed values. The similarity in the pharma-
cokinetic parameters of the 4 products hows that there i~
very little difference, if any. in the availability of sulpha-
furazole from the different brand of tablets, and all 4 pro-
ducts can be regarded as equally effective.
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